Showing 4801-4810 of 9773 results for "".
- Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitishttps://practicaldermatology.com/news/reduced-dose-tralokinumab-maintains-symptom-control-for-up-to-1-year-in-atopic-dermatitis/2485613/Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April
- Aesthetic Sequelae of GLP-1 Receptor Agonists Highlighted in Clinical Reviewhttps://practicaldermatology.com/news/aesthetic-sequelae-of-glp-1-receptor-agonists-highlighted-in-clinical-review/2485615/Dermatologists are increasingly encountering aesthetic complications associated with GLP-1 receptor agonist (RA)–induced weight loss, according to a clinical review presented at the South Beach Symposium. The poster, b
- FDA Accepts Galderma’s RelabotulinumtoxinA BLA Resubmissionhttps://practicaldermatology.com/news/fda-accepts-galdermas-relabotulinumtoxina-bla-resubmission/2485601/Galderma announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess™) for the temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines in a
- Doxycycline and Minocycline Show Benefit in OLP Gingival Lesionshttps://practicaldermatology.com/news/doxycycline-and-minocycline-show-benefit-in-olp-gingival-lesions/2485468/A retrospective analysis suggests doxycycline and minocycline may offer an effective systemic option for patients with inflammatory oral lichen planus (OLP) involving the gingiva who fail to respond to topical agents. Study res
- No New Safety Signals in Broad Ruxolitinib Dataset, Including AD, Vitiligo, and AAhttps://practicaldermatology.com/news/no-new-safety-signals-in-broad-ruxolitinib-dataset-including-ad-vitiligo-and-aa/2485382/A new safety analysis presented at the 2026 Winter Clinical Dermatology Conference in Maui supporting the long-term tolerability of ruxolitinib cream (Opzelura®, Incyte) in a range of inflammatory skin conditions. The integrat
- Dr. Amy McMichael Highlights Breakthrough Alopecia Therapieshttps://practicaldermatology.com/news/dr-amy-mcmichael-highlights-breakthrough-alopecia-therapies/2485364/Anyone not using low-dose oral minoxidil yet has “missed the boat.” That was the message from Amy McMichael, MD, during her presentation on non-scarring hair loss at the 2026 Winter Clinical Dermatology Conference in Hawaii. Dr. McMichael, who before her presentation was named the conferen
- Vitiligo Linked to Elevated Risk of Herpes Zoster: Cohort Studyhttps://practicaldermatology.com/news/vitiligo-linked-to-elevated-risk-of-herpes-zoster-study-finds/2485328/A new cohort study from Taiwan indicated vitiligo is independently associated with a heightened risk of herpes zoster (HZ), with systemic immunosuppressive therapies compounding the risk further. Using data from Taiwan's Longit
- Analysis: CHL-Fe-based PDT Shows Activity Against Drug-Resistant C. acneshttps://practicaldermatology.com/news/chl-febased-photodynamic-therapy-shows-potent-activity-against-drug-resistant-c-acnes/2485327/Photodynamic therapy (PDT) using sodium iron chlorophyllin (CHL-Fe) and red light achieved consistent bactericidal effects against drug-resistant Cutibacterium acnes (C. acnes) strains in vitro, according to new study finding
- Analysis: Ustekinumab, IL-23 Inhibitors Show Higher Drug Survival in Psoriasishttps://practicaldermatology.com/news/analysis-ustekinumab-il-23-inhibitors-show-higher-drug-survival-in-psoriasis/2485295/A new Danish cohort study using data from the DERMBIO registry suggests ustekinumab was linked with the best 5-year survival of comparators in bionaive patients with psoriasis. The analysis included a total of 7,193 treatment
- TOGETHER-PsA: Weight Loss Plus PsA Control with Ixekizumab and Tirzepatidehttps://practicaldermatology.com/news/together-psa-weight-loss-plus-psa-control-with-ixekizumab-and-tirzepatide/2485259/In the phase 3b TOGETHER-PsA trial, ixekizumab (Taltz, Eli Lilly) used in combination with tirzepatide (Zepbound, Eli Lilly) was more effective than ixekizumab monotherapy in adults with active psoriatic arthritis (PsA) who also have obesity or are overweight with a